{"page":{"totalFilteredElements":28},"studies":[{"active":true,"description":"Prospektive Beobachtungsstudie mit Erstellung einer Biodatenbank zur Untersuchung potentieller Biomarker f&#252;r Risikostratifizierung, Therapiesteuerung und Vertr&#228;glichkeit in Patient*innen mit neuroendokrinen Neoplasien (NENReg)","eudractNumber":null,"id":11499,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn3","name":"Eierstockkrebs (Ovarialkarzinom)"},{"id":"pro","name":"Prostatakrebs"},{"id":"gio","name":"Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)"},{"id":"gio1","name":"Karzinom der Speiseröhre (Oesophaguskarzinom, inkl. gastrooesophagealer Übergang)"},{"id":"gio2","name":"Karzinom des gastrooesophagealen Übergangs"},{"id":"gio3","name":"Magenkarzinom"},{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"},{"id":"giu3","name":"Bauchspeicheldrüsenkrebs (Pankreaskarzinom)"},{"id":"hno","name":"Kopf/Hals Tumoren"},{"id":"hno1","name":"Mundhöhlenkarzinom, Rachenkarzinom, inkl. Mundboden- und Zungengrundkarzinom"},{"id":"hno2","name":"Kehlkopfkrebs (Larynxkarzinom)"},{"id":"nen","name":"Bösartige Tumoren der Nebenniere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2025-11-01T09:14:44+01:00","shortTitle":"NENReg","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Nationales Netzwerk Genomische Medizin Lungenkrebs nNGM","eudractNumber":null,"id":4357,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun1","name":"Kleinzelliges Bronchialkarzinom (SCLC)"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"}],"mutations":[],"nctNumber":"NCT05934032","phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2018-01-01T10:03:00+01:00","shortTitle":"Nationales Netzwerk Genomische Medizin Lungenkrebs nNGM","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Patienten-Typologisierung f&#252;r ein bedarfsgerechtes und effektiveres Coaching bei Patientinnen mit Hormonrezeptor positivem Mammakarzinom / <b>PaTyp</b><div><b><br /></b></div><div><b>VERSORGUNGSFORSCHUNGSSTUDIE</b><b><br /></b></div>","eudractNumber":null,"id":7720,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"}],"mutations":[{"name":"ER (Östrogenrezeptor)","id":"mt_248"},{"name":"PgR (Progesteronrezeptor)","id":"mt_221"}],"nctNumber":null,"phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2024-03-12T14:28:59+01:00","shortTitle":"PaTyp","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Patienten-Typologisierung f&#252;r ein bedarfsgerechtes und effektiveres Coaching bei Patientinnen mit Hormonrezeptor positiven MammaCa / PaTyp<div><br /></div><div><b>VERSORGUNGSFORSCHUNGSSTUDIE</b></div>","eudractNumber":null,"id":10616,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"}],"mutations":[{"name":"ER (Östrogenrezeptor)","id":"mt_248"},{"name":"PgR (Progesteronrezeptor)","id":"mt_221"}],"nctNumber":null,"phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2024-03-13T08:39:41+01:00","shortTitle":"PaTyp","therapeutical":false,"therapyLines":[]},{"active":true,"description":"A&#160;Retrospective, Multicountry Study of Clinical Outcomes in Patients with Relapsed/ Refractory Multiple Myeloma Treated with T-cell Redirectors Outside of Clinical Trials (REALiTEC)<br /><div>\n  64007957MMY4004\n  [REALiTEC]</div>","eudractNumber":null,"id":8882,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":"NCT06285318","phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2024-05-01T10:04:17+02:00","shortTitle":"REALiTEC","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Effekt einer zus&#228;tzlichen Braun-Fu&#223;punkt-Anastomose bei Patienten nach Pankreaskopfresektion<div>DFG&#160;- Projektnummer 416055422<br /></div><div><br /></div>","eudractNumber":null,"id":7837,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu3","name":"Bauchspeicheldrüsenkrebs (Pankreaskarzinom)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2022-07-28T12:12:42+02:00","shortTitle":"RECOPS","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Simultan integrierter Boost in der HNO Quality Control Registry","eudractNumber":null,"id":2554,"indications":[{"id":"hno","name":"Kopf/Hals Tumoren"},{"id":"hno3","name":"Kopf-Hals-Malignome"}],"mutations":[],"nctNumber":"NCT06831903","phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2019-10-01T13:24:30+02:00","shortTitle":"Register SIB HNO","therapeutical":false,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"SURVIVE (Standard Surveillance vs. Intensive Surveillance in Early Breast Cancer) - a partially double-blinded, multicenter, randomized, controlled superiority study<div><br /></div><div>DRKS00030745<br /></div>","eudractNumber":null,"id":9451,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"}],"mutations":[],"nctNumber":"NCT05658172","phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2024-03-25T09:29:48+01:00","shortTitle":"SURVIVE","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]}]}